Area of research
Epidemiology · Hepatology
Research interest
Dr. Kleiner is currently participating in two multicenter clinical networks focused on non-alcoholic fatty liver disease sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. These two efforts: the NASH Clinical Research Network and the Longitudinal Assessment of Bariatric Surgery will provide both cross-sectional and longitudinal data that will allow evaluation of prognostic factors in fatty liver disease, which may be present 20 to 25% of the U.S. population. Dr. Kleiner is the reference pathologist for the Drug-Induced Liver Injury Network (DILIN). This is an NIDDK-sponsored clinical research network interested in prospective evaluation and investigation of drug-induced liver injury (DILI)is one of the main reasons for removal of drugs from the market. Dr.
Clinical and HLA Associations of Fluoroquinolone-Induced Liver Injury: Results From the Drug-Induced Liver Injury Network.
Genetic and non-genetic drivers of histological progression and regression in MASLD.
Hepatic Manifestations and Response to Treatment in Deficiency of Adenosine Deaminase 2.
Differential intrahepatic integrated HBV DNA patterns between HBeAg-positive and HBeAg-negative chronic hepatitis B.
Exceptionally Long Recurrence-Free Survival in a Male Patient With Fibrolamellar Hepatocellular Carcinoma.
Portal Vein Tryptophan Pathway Analysis Reveals Gut-Mediated Inflammatory Pathway Predominance in HCV Infection.
Automated Delineation of Couinaud Segments on CT for Future Liver Remnant Volumetry.
Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial
Deconvolution of cell types and states in spatial multiomics utilizing TACIT.
Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab.
Role of liver biopsy in the management of idiosyncratic DILI.
Genetic and non-genetic drivers of histological progression and regression in MASLD
Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials
Clinical and HLA Associations of Fluoroquinolone-Induced Liver Injury: Results From the Drug-Induced Liver Injury Network
Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network.
Making Sense of 'Porto-Sinusoidal Vascular Disorder': What Does It Mean for the Pathologist and the Patient?
Portal sinusoidal vascular diseases: Assessment and therapy.
Integrated Spheroid-to-Population Framework for Evaluating PFHpA-Associated Metabolic Dysfunction and Steatotic Liver Disease
A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion
Autoimmune-Like Hepatitis Following Hepatic Graft-Versus-Host Disease in an Allogenic Hematopoietic Cell Transplant Recipient.
Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy.
Association between pattern of hepatic iron deposition and severity of MASH among patients enrolled in the NASH Clinical Research Network.
Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents.
Table S5 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Table S1 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Exhausted-like effector CD8 T cells mediate immune-stromal interactions at mucosal Chronic Graft-versus-Host Disease onset
Figure S4 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Figure 2 extended data from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Table S3 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes